The South European Uroncological Group has conducted a phase III trial comparing intermittent androgen deprivation with continuous therapy in patients with advanced prostate cancer. The intermittent regimen was found to be non-inferior in terms of disease progression, survival, and quality of life. Nevertheless, the implications of such research for patient management remain controversial.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Intermittent versus continuous androgen deprivation for locally advanced, recurrent or metastatic prostate cancer: a systematic review and meta-analysis
BMC Urology Open Access 25 January 2014
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Calais da Silva, F. E. et al. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group. Eur. Urol. 55, 1269–1277 (2009).
Thompson, C. A. et al. Andropause: symptom management for prostate cancer patients treated with hormonal ablation. Oncologist 8, 474–487 (2003).
Keating, N. L., O'Malley, A. J. & Smith, M. R. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J. Clin. Oncol. 24, 4448–4456 (2006).
Bruchovsky, N. et al. Quality of life, morbidity, and mortality results of a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen relapse after radiation therapy for locally advanced prostate cancer. Clin. Genitourin. Cancer 6, 46–52 (2008).
Akakura, K. et al. Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigen. Cancer 71, 2782–2790 (1993).
Sato, N. et al. Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study. Urology 64, 341–345 (2004).
Miller, K. et al. Randomised prospective study of intermittent versus continuous androgen suppression in advanced prostate cancer [abstract #5015]. J. Clin. Oncol. 25 (Suppl. 18S), 5015 (2007).
Loblaw, D. A. et al. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J. Clin. Oncol. 25, 1596–1605 (2007).
Heidenreich, A. et al. European Association of Urology. EAU guidelines on prostate cancer. Eur. Urol. 53, 68–80 (2008).
Hussain, M. et al. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J. Clin. Oncol. 24, 3984–3990 (2006).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
M. A. Carducci has been a consultant for, and received grant/research support from, AstraZeneca. D. Keizman declares no competing interests.
Rights and permissions
About this article
Cite this article
Keizman, D., Carducci, M. Intermittent androgen deprivation—questions remain. Nat Rev Urol 6, 412–414 (2009). https://doi.org/10.1038/nrurol.2009.145
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2009.145
